Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–87 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypercortisolemia Clear all
Recruiting Phase 4 Interventional

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

NCT07247162
View directory record Official record
Conditions
Hypertension, Hypercortisolemia, Cushing Syndrome
Interventions
Osilodrostat, Placebo
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Jacksonville, Florida • Canton, Ohio • Weslaco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Recruiting Phase 2 Interventional

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions
Metyrapone 250 mg Oral Tablets, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639
View directory record Official record
Conditions
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 dose
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328
View directory record Official record
Conditions
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions
SPI-62, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 30, 2026, 10:20 AM EDT
Completed Not applicable Interventional Results available

A Translational Approach to Gitelman Syndrome

NCT00822107
View directory record Official record
Conditions
Gitelman Syndrome
Interventions
Hydrochlorothiazide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 30, 2026, 10:20 AM EDT
Terminated No phase listed Observational

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

NCT03379363
View directory record Official record
Conditions
Hypercortisolism, Cushing Syndrome
Interventions
Not listed
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
Up to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 30, 2026, 10:20 AM EDT
Active, not recruiting No phase listed Observational

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156
View directory record Official record
Conditions
Endogenous Cushing's Syndrome
Interventions
Osilodrostat
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 30, 2026, 10:20 AM EDT
Completed Phase 4 Interventional

MR Antagonist and LSD1

NCT04840342
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Excess
Interventions
Eplerenone, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
17 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Completed No phase listed Observational

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

NCT00004354
View directory record Official record
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 10:20 AM EDT
Completed No phase listed Observational Results available

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

NCT02310269
View directory record Official record
Conditions
Cushings Disease
Interventions
Pasireotide
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 10:20 AM EDT
Completed No phase listed Observational

Study of Adrenal Gland Tumors

NCT00005927
View directory record Official record
Conditions
Adrenal Gland Neoplasm
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Calcium Channel Blockade in Primary Aldosteronism

NCT04179019
View directory record Official record
Conditions
Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Interventions
Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 30, 2026, 10:20 AM EDT
Completed No phase listed Observational

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT03817840
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Treatment of Cushing's
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 30, 2026, 10:20 AM EDT